Cerulean Pharma traded at $1.47 this Friday March 4th, increasing $0.01 or 0.68 percent since the previous trading session. Looking back, over the last four weeks, Cerulean Pharma gained 9.26 percent. Over the last 12 months, its price fell by 24.23 percent. Looking ahead, we forecast Cerulean Pharma to be priced at 1.43 by the end of this quarter and at 1.31 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Adamis Pharmaceuticals 0.33 -0.02 -5.26% -66.74%
Agile Therapeutics 0.57 -0.08 -11.93% -45.15%
Arrowhead Research 47.29 1.66 3.64% -21.86%
Bayer 54.15 2.47 4.78% 13.31%
Brainstorm Cell Therapeutics 3.50 0.55 18.64% -4.89%
Biocept 1.17 -0.03 -2.50% -70.75%
Immunogen 5.43 0.19 3.63% 0.93%
Incyte Corp 73.99 0.23 0.31% 0.71%
J&J 165.30 -1.84 -1.10% -6.21%
MacroGenics 5.22 0.13 2.55% -77.49%
Merck & Co 91.02 2.09 2.35% 18.64%
Nektar Therapeutics 5.14 0.19 3.84% -64.03%
Pfizer 50.11 1.82 3.77% 3.36%
Perrigo 41.87 0.22 0.53% 2.25%
Seattle Genetics 170.14 -3.90 -2.24% 8.76%

Indexes Price Day Year
USND 13047 267.27 2.09% -11.98%

Cerulean Pharma
Cerulean Pharma Inc. is a clinical-stage, oncology-focused company applying its tumor targeting platform to develop therapies. The Companys nanoparticle-drug conjugate product candidates consist of polymers that are covalently linked to anti-cancer therapeutics, or payloads. Its lead product candidate, CRLX101, is in Phase II clinical development and can address cancer therapies. CRLX101 is designed to be a dual inhibitor of topoisomerase 1 and hypoxia-inducible factor-1 alpha (commonly referred to as HIF-1alpha). Its second product candidate, CRLX301, is a nanopharmaceutical with docetaxel, a microtubule stabilizer, as its anti-cancer payload. CRLX301 is designed to act as a tubulin inhibitor. The Companys ribonucleic acid (RNA) delivery program has produced a variety of RNA-containing NDCs that can overcome the challenges of RNA administration.